FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Flavia Filippetti

Research Profile

Physiology

Anatomy

Chemicals & Drugs

Disorders

Ovarian Neoplasms

Procedures

Co-author Network

Publications

TOP 3
Simona Mozzetti; Silvia Prislei; Giuseppina Raspaglio; Giovanni Scambia; Shohreh Shahabi; Marta De Donato; Flavia Filippetti; Enrica Martinelli; Ferlini Cristiano
Gli family transcription factors are drivers of patupilone resistance in ovarian cancer.
Silvia Prislei; Marisa Mariani; Giuseppina Raspaglio; Simona Mozzetti; Flavia Filippetti; Gabriella Ferrandina; Giovanni Scambia; Ferlini Cristiano
RON and cisplatin resistance in ovarian cancer cell lines.
Lucia Cicchillitti; Roberta Penci; Michela Di Michele; Flavia Filippetti; Domenico Rotilio; Maria Benedetta Donati; Giovanni Scambia; Ferlini Cristiano
Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Flavia Filippetti (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Simona Mozzetti; Silvia Prislei; Giuseppina Raspaglio; Giovanni Scambia; Shohreh Shahabi; Marta De Donato; Flavia Filippetti; Enrica Martinelli; Ferlini Cristiano
Gli family transcription factors are drivers of patupilone resistance in ovarian cancer.
Biochemical pharmacology 2012;84(11):1409-18.
2010: Silvia Prislei; Marisa Mariani; Giuseppina Raspaglio; Simona Mozzetti; Flavia Filippetti; Gabriella Ferrandina; Giovanni Scambia; Ferlini Cristiano
RON and cisplatin resistance in ovarian cancer cell lines.
Oncology research 2010;19(1):13-22.
2008: Lucia Cicchillitti; Roberta Penci; Michela Di Michele; Flavia Filippetti; Domenico Rotilio; Maria Benedetta Donati; Giovanni Scambia; Ferlini Cristiano
Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin.
Molecular cancer therapeutics 2008;7(7):2070-9.
2008: Giuseppina Raspaglio; Flavia Filippetti; Silvia Prislei; Roberta Penci; Ilaria De Maria; Lucia Cicchillitti; Simona Mozzetti; Giovanni Scambia; Ferlini Cristiano
Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region.
Gene 2008;409(1-2):100-8.
2008: Silvia Prislei; Simona Mozzetti; Flavia Filippetti; Marta De Donato; Giuseppina Raspaglio; Lucia Cicchillitti; Giovanni Scambia; Ferlini Cristiano
From plasma membrane to cytoskeleton: a novel function for semaphorin 6A.
Molecular cancer therapeutics 2008;7(1):233-41.
2005: Ferlini Cristiano; Giuseppina Raspaglio; Simona Mozzetti; Lucia Cicchillitti; Flavia Filippetti; Daniela Gallo; Caterina Fattorusso; Giuseppe Campiani; Giovanni Scambia
The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
Cancer research 2005;65(6):2397-405.
2005: Simona Mozzetti; Ferlini Cristiano; Paola Concolino; Flavia Filippetti; Giuseppina Raspaglio; Silvia Prislei; Daniela Gallo; Enrica Martinelli; Franco O Ranelletti; Gabriella Ferrandina; Giovanni Scambia
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):298-305.
2004: Paola Concolino; Valerio Papa; Simona Mozzetti; Ferlini Cristiano; Fabio Pacelli; Enrica Martinelli; Riccardo Ricci; Flavia Filippetti; Giovanni Scambia; Giovanni Battista Doglietto
The unsolved enigma of CDH1 down-regulation in hereditary diffuse gastric cancer.
The Journal of surgical research 2004;121(1):50-5.
2003: Ferlini Cristiano; Giuseppina Raspaglio; Simona Mozzetti; Mariagrazia Distefano; Flavia Filippetti; Enrica Martinelli; Gabriella Ferrandina; Daniela Gallo; Franco O Ranelletti; Giovanni Scambia
Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.
Molecular pharmacology 2003;64(1):51-8.